Charles River Laboratories International (CRL) Stock Forecast & Price Target

$204.26

+1.76 (+0.87%)

(As of 08/21/2024 ET)

Charles River Laboratories International - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for Charles River Laboratories International in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 10 have given a hold rating, and 4 have given a buy rating for CRL.

Consensus Price Target

$231.00
13.09% Upside

High Forecast	$290.00
Average Forecast	$231.00
Low Forecast	$191.00

According to the 14 analysts' twelve-month price targets for Charles River Laboratories International, the average price target is $231.00. The highest price target for CRL is $290.00, while the lowest price target for CRL is $191.00. The average price target represents a forecasted upside of 13.09% from the current price of $204.26.

Type	Current Forecast 8/23/23 to 8/22/24	1 Month Ago 7/24/23 to 7/23/24	3 Months Ago 5/25/23 to 5/24/24	1 Year Ago 8/23/22 to 8/23/23
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	10 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$231.00	$252.29	$255.27	$247.80
Forecasted Upside	13.09% Upside	15.19% Upside	13.49% Upside	16.72% Upside

Get Charles River Laboratories International Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

Ad Investors Alley

Grab this ETF paying a huge 22% dividend

Imagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck worries melt away...

All because of one ETF paying a huge 22% dividend.

CRL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Charles River Laboratories International Stock vs. The Competition

Type	Charles River Laboratories International	Medical Companies	S&P 500
Consensus Rating Score	2.29	2.75	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	13.09% Upside	5,591.79% Upside	8.74% Upside
News Sentiment Rating	Neutral News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/12/2024	TD Cowen 4 of 5 stars		Lower Target	Hold ➝ Hold	$228.00 ➝ $203.00	+2.82%
8/8/2024	Baird R W 0 of 5 stars	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/8/2024	Barclays 3 of 5 stars	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$230.00 ➝ $210.00	+5.42%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$290.00 ➝ $240.00	+22.29%
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$265.00 ➝ $225.00	+12.52%
8/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$290.00 ➝ $250.00	+25.03%
Get the Latest News and Ratings for CRL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.
8/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$239.00 ➝ $191.00	-4.48%
8/8/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$270.00 ➝ $205.00	+2.52%
6/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/7/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$235.00	+6.04%
2/15/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$215.00 ➝ $250.00	+4.30%
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
11/10/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$220.00 ➝ $205.00	+19.19%
9/22/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$280.00 ➝ $275.00	+38.78%
9/22/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$245.00 ➝ $230.00	+16.07%
5/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $250.00	+31.01%
5/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $255.00	+30.27%
3/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold	$233.00 ➝ $203.00	+2.81%
11/2/2022	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Smock Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:01 AM ET.

CRL Forecast - Frequently Asked Questions

What is Charles River Laboratories International's forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Charles River Laboratories International is $231.00, with a high forecast of $290.00 and a low forecast of $191.00.
Should I buy or sell Charles River Laboratories International stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRL, but not buy additional shares or sell existing shares.
Does Charles River Laboratories International's stock price have much upside?: According to analysts, Charles River Laboratories International's stock has a predicted upside of 13.06% based on their 12-month stock forecasts.
Has Charles River Laboratories International been downgraded by Wall Street analysts recently?: Over the previous 90 days, Charles River Laboratories International's stock had 3 downgrades by analysts.
What analysts cover Charles River Laboratories International?: Charles River Laboratories International has been rated by research analysts at Argus, Baird R W, Barclays, Evercore ISI, JPMorgan Chase & Co., Mizuho, Robert W. Baird, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
Do Wall Street analysts like Charles River Laboratories International more than its competitors?: Analysts like Charles River Laboratories International less than other "medical" companies. The consensus rating for Charles River Laboratories International is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRL compares to other companies.